11/20
04:15 pm
mura
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Low
Report
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
11/13
07:00 am
mura
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
Neutral
Report
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
11/11
08:10 am
mura
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
11/11
07:00 am
mura
Mural Oncology to Participate in Two Upcoming Investor Conferences
Low
Report
Mural Oncology to Participate in Two Upcoming Investor Conferences
11/7
04:15 pm
mura
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Medium
Report
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
11/4
04:15 pm
mura
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/17
08:55 am
mura
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Medium
Report
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
10/7
07:00 am
mura
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Medium
Report
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10/4
08:06 am
mura
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $18.00 price target on the stock.
Medium
Report
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $18.00 price target on the stock.
10/2
04:15 pm
mura
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/30
12:26 pm
mura
Mural Oncology Highlights Clinical Trials During It's Maiden Investor Day [Forbes]
Low
Report
Mural Oncology Highlights Clinical Trials During It's Maiden Investor Day [Forbes]
9/26
07:00 am
mura
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
Medium
Report
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
9/23
07:00 am
mura
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
Medium
Report
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
9/10
07:00 am
mura
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
Low
Report
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
9/4
04:30 pm
mura
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/27
07:00 am
mura
Mural Oncology to Present at Two Upcoming Investor Conferences
Low
Report
Mural Oncology to Present at Two Upcoming Investor Conferences